Results 151 to 160 of about 78,668 (187)

HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. [PDF]

NAR Cancer
Ling H, Li Y, Peng C, Yang S, Seto E.
europepmc   +1 more source

A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer. [PDF]

JAAD Int
Katz S, Ciuba D, Ribas A, Shelach N, Zelinger G, Barrow B, Corn BW.   +6 more
europepmc   +1 more source

Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma. [PDF]

J Immunother Cancer
Hornsteiner F, Vierthaler J, Strandt H, Resag A, Fu Z, Ausserhofer M, Tripp CH, Dieckmann S, Kanduth M, Farrand K, Bregar S, Nemati N, Hermann-Kleiter N, Seretis A, Morla S, Mullins D, Finotello F, Trajanoski Z, Wollmann G, Ronchese F, Schmitz M, Hermans IF, Stoitzner P.   +22 more
europepmc   +1 more source

BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells. [PDF]

Int J Mol Sci
Zanrè V, Bellinato F, Cardile A, Passarini C, Di Bella S, Menegazzi M.   +5 more
europepmc   +1 more source

Single-cell genomics analysis reveals complex genetic interactions in an <i>in vivo</i> model of acquired BRAF inhibitor resistance. [PDF]

NAR Cancer
Schillo JL, Feddersen CR, Peplinski RM, Powell LS, Varzavand A, Stipp CS, Riordan JD, Dupuy AJ.   +7 more
europepmc   +1 more source